new currency for united states Top Reviews

Shisi Pharmaceutical Group: Dilalos dispersible tablets (125mg) have obtained the approval of pharmaceutical production registration. Shisi Pharmaceutical Group announced on the Hong Kong Stock Exchange on December 10th that it has obtained the approval of pharmaceutical production registration of Dilalos dispersible tablets (125mg) in National Medical Products Administration, China, which belongs to the fourth category of chemicals and is deemed to have passed the consistency evaluation. Deslorax dispersible tablets are mainly used to treat chronic iron overload caused by frequent blood transfusion in patients with β -thalassemia over two years old, and chronic iron overload in patients with transfusion-independent thalassemia syndrome over 10 years old.Allianz's investment in the national pension was approved. It was learned from the national pension that the State Financial Supervision and Administration recently officially approved the change of the registered capital of the National Pension Insurance Co., Ltd. and added Allianz Investment Co., Ltd. as a shareholder of the company. (CSI Taurus)Dotinolole, a new drug used by Weicai to treat gout, was approved for marketing in China. On December 10th, Weicai China announced that its new urate reuptake inhibitor Dotinolole tablets (trade name: Youlesi) had been approved by National Medical Products Administration (NMPA) in China, and its indication was gout with hyperuricemia.

Israel attacked the Syrian capital and its surrounding areas again. Syrian local media released a message today (December 10) that Israel once again launched an attack on the Syrian capital Damascus and its surrounding areas. According to Agence France-Presse, the Syrian capital Damascus heard a huge explosion today (December 10).Research Report: In the third quarter, the installed capacity of traction inverters for electric vehicles in China accounted for 61% of the world. According to the latest research of TrendForce Jibang Consulting, the total installed capacity of traction inverters for electric vehicles in the third quarter of 2024 reached 6.87 million, which was 7% higher than that in the same period last year, but the growth rate has been reduced. In the competition pattern of first-class suppliers, BYD benefited from the hot sales of its models. In the third quarter, the installed market share of traction inverter increased by 1% to 18%, surpassing Denso of Japanese factory for the first time and becoming the company with the highest market share. The market share of Huichuan Technology has also increased to 6%, which shows that the competitiveness of China manufacturers in this field continues to increase. Generally speaking, China manufacturers, Japanese manufacturers and Tesla together account for half of the global installed capacity, while the influence of European and American manufacturers is gradually weakening. TrendForce Jibang Consulting indicated that the regional differentiation of traction inverters is becoming more and more obvious, with the installed capacity in China accounting for 61% of the global total. Under the pressure of shrinking market, Europe is actively reforming and cutting expenditure to enhance the competitiveness of the electric vehicle industry chain. In the short term, the stable demand in China market will continue to support the growth of traction inverter market. In the long run, if the European automobile industry chain can be successfully reformed, it will help boost the overall performance of the global traction inverter and electric vehicle market.Afternoon comment: The Shanghai Composite Index rose more than 1% in half a day, and consumer concept stocks broke out collectively. The index was active in early trading. The Shanghai Composite Index rose more than 1% in half a day, and the Shanghai Composite Index rose more than 2%. In terms of sectors, robot concept stocks continued to break out, and the concept of PEEK materials led the rise. Both China Research Institute and Xinyi New Materials had a daily limit of 20cm, while Zhongxin Fluorescent Materials and Walter shares touched the daily limit; The large consumer sector collectively rose, with dairy stocks leading the gains, and Panda Dairy, Western Animal Husbandry and Li Ziyuan were trading daily; AI concept stocks fluctuated higher, and it is worth buying 20cm daily limit, Hanwang Technology, Xinhua Media and other daily limit; Insurance stocks strengthened, and Tianli Technology, Astar, Focus Technology and other daily limit. Overall, individual stocks showed a general upward trend, with more than 4,600 stocks rising. On the disk, all sectors in the two cities generally rose, with PEEK materials, film and television theaters and dairy sectors among the top gainers.

Israel once again launched an attack on Damascus and its surrounding areas in Syria. On the 10th local time, it was learned from the Syrian media that Israel once again launched an attack on Damascus, the capital of Syria, and its surrounding areas. At present, the Israeli side has no response to this. (CCTV)Heavy meeting set the tone! The turnover of A-shares exceeded one trillion yuan for 50 consecutive trading days, focusing on the opportunities of core assets of A50ETF Huabao (159596). On December 10th, the A-share market rose across the board, and the turnover of Shanghai and Shenzhen stock markets exceeded one trillion yuan for the 50th consecutive trading day, setting a new record. By midday, A50ETF Huabao (159596) had increased by 1.98%, with a turnover of 101 million yuan. In terms of constituent stocks, the top ten awkward stocks rose more and fell less. CITIC Securities led the gains, and China Ping An, China Merchants Bank and other stocks followed suit. According to changjiang securities's analysis, "moderately loose monetary policy" indicates abundant liquidity and broad-spectrum interest rate is still in the downward channel, which is expected to benefit bonds and stocks from the denominator. The "more active fiscal policy" and "all-round expansion of domestic demand" indicate that the broad credit policy is expected to continue to increase, and it is expected to support the price of equity assets from the molecular side.Australia's S&P/ASX200 index has narrowed its decline and is now down 0.3%.